PT-141, also called bremelanotide, is a melanocortin receptor agonist used for sexual desire and arousal concerns. The FDA-approved brand Vyleesi is indicated for certain premenopausal women with acquired, generalized HSDD. Other uses may be off-label. Safer access means working with a licensed clinician, not buying research-use-only peptides for human use.
Wondering if peptide therapy is right for you? Take the 3-min clinical quiz.
See if you qualify →What should you know before buying PT-141 peptide online?
Before buying PT-141 online, the key question is whether you are getting a prescribed medication through a licensed clinician and pharmacy, or a research chemical not meant for human use. The difference matters because bremelanotide can affect blood pressure, heart rate, nausea risk, and medication safety.
The FDA-approved bremelanotide product is Vyleesi, an injection indicated for acquired, generalized hypoactive sexual desire disorder, or HSDD, in certain premenopausal women 1. The pivotal RECONNECT trials evaluated sexual desire and distress scores in this population, not every cause of low libido, arousal concern, or erectile dysfunction 2.
- Generic name: bremelanotide.
- Also known as: PT-141.
- Brand name: Vyleesi.
- Drug class: melanocortin receptor agonist.
- FDA-approved use: acquired, generalized HSDD in certain premenopausal women.
- Chia form: compounded PT-141 nasal spray, when prescribed after clinician review.
What is PT-141 used for?
PT-141 is mainly discussed for low sexual desire and arousal concerns. The strongest human evidence is for bremelanotide injection in certain premenopausal women with acquired, generalized HSDD, while other uses have less evidence or may be off-label.
Low sexual desire and HSDD
HSDD means low sexual desire that causes distress and is not better explained by another medical, relationship, medication, or mental-health issue. In the FDA label, Vyleesi is indicated for acquired, generalized HSDD in premenopausal women, with important limits: it is not indicated for HSDD due to a co-existing medical or psychiatric condition, relationship problems, or medication effects 1.
In the phase 3 RECONNECT trials, bremelanotide was studied using patient-reported desire and distress measures over 24 weeks 2. Individual results vary, and those trial results apply to the studied drug and population, not automatically to every compounded formulation or off-label use.
Arousal concerns
Bremelanotide has also been studied in female sexual dysfunction more broadly, including sexual arousal disorder, but FDA approval is narrower than “arousal problems” in general 3. Arousal concerns can come from hormones, pelvic pain, medications, mood, stress, relationship factors, menopause, or circulation, so a clinician should first clarify the main problem.
Off-label interest in men and erectile dysfunction
PT-141 has been investigated in men with erectile dysfunction, including early studies of intranasal bremelanotide in men with mild-to-moderate erectile dysfunction 4. This is not the same as FDA approval for men, and side effects and cardiovascular screening still matter because bremelanotide can change blood pressure and heart rate 1.
Why evidence differs by sex and indication
Sexual function is not one problem. Desire, arousal, erection quality, orgasm, pain, relationship context, and distress are different clinical questions. That is why evidence for acquired, generalized HSDD in premenopausal women should not be stretched to every libido or erectile concern 5.
How does PT-141 work in the body?
Bremelanotide works through melanocortin receptor signaling in the central nervous system. In plain English, it acts more on brain pathways tied to sexual desire and arousal than on blood-vessel widening alone.
PT-141 is a synthetic cyclic peptide related to melanocortin signaling. Reviews describe activity at melanocortin receptors, including MC3R and MC4R, which are found in brain regions involved in sexual motivation, including the hypothalamus 3.
This makes PT-141 different from PDE5 inhibitors such as sildenafil and tadalafil. PDE5 inhibitors mainly support erectile response by affecting nitric-oxide and smooth-muscle signaling in blood vessels, while bremelanotide is described as centrally acting through melanocortin pathways 6.
That difference does not make PT-141 better for every person. It simply means the clinical question is different: is the concern desire, arousal, erection firmness, medication side effects, pain, mood, hormones, or something else?
Is PT-141 FDA approved?
Vyleesi is FDA-approved, but only for a specific use: acquired, generalized HSDD in certain premenopausal women. PT-141 use outside that labeled population may be off-label.
The FDA-approved product is bremelanotide injection under the brand name Vyleesi. The label states that it is not indicated for HSDD in postmenopausal women or in men, and it is not indicated to enhance sexual performance 1.
Off-label use means a clinician is considering a medication for a use, population, dose form, or route that is not in the FDA-approved label. Off-label prescribing can be legal when done by a licensed clinician, but it should come with clear discussion of evidence limits, risks, and follow-up.
Compounded PT-141 also differs from Vyleesi. A compounded formulation is made for an individual patient by a licensed compounding pharmacy when prescribed, but it does not have FDA-reviewed outcomes data the way an approved drug label does 7.
What are the safer ways to buy PT-141?
The safer path for PT-141 is prescription access through a licensed clinician, with dispensing by a licensed pharmacy when clinically appropriate. Avoid treating research-use-only peptide vials as human medication.
A clinician should review blood pressure, heart history, medications, pregnancy status where relevant, the nature of the sexual concern, and whether the intended use matches the FDA-approved indication or is off-label. Vyleesi labeling includes warnings about transient blood pressure increases and heart-rate decreases, and advises against use in people with uncontrolled hypertension or known cardiovascular disease 1.
Licensed compounding pharmacy access is different from buying a vial marked “for research use only.” FDA guidance and enforcement materials distinguish prescription drug compounding from products marketed outside normal drug-approval or pharmacy channels 7.
- Look for clinician review before prescribing, not checkout-only access.
- Confirm the pharmacy is state-licensed and dispenses for patient use under a prescription.
- Avoid “research-use-only” products for self-use, even if the website lists purity testing.
- Be cautious with sites that promise results, skip health history, or sell peptide powders with reconstitution instructions for consumers.
- Ask how side effects and follow-up messages are handled after the medication ships.
3-min quiz
Considering PT-141 with clinician review?
Chia offers compounded PT-141 nasal spray when prescribed after an online medical evaluation by a licensed US provider. A prescription is not guaranteed, and compounded drugs are not FDA-approved. You can start with Chia’s secure eligibility quiz.
Buying PT-141 at Chia: nasal spray, clinician review, and prescription delivery
At Chia, PT-141 nasal spray access starts with a 100% online visit. Plans currently start at $159/month, and a licensed US provider prescribes only when clinically appropriate.
Chia offers PT-141 as a compounded nasal spray. PT-141 is also available through Chia’s Spark protocol, which currently starts at $159/month. Pricing can change, so the product and protocol pages are the best place to check current details.
Here is how care works: you complete a short health questionnaire, a licensed US provider reviews your history and goals, and medication is prescribed only if it fits your safety profile. If prescribed, the medication is compounded in the US by a state-licensed 503A compounding pharmacy and shipped to your door.
Dosing is provider-guided and adjusted over time when needed. You can message your care team through the patient portal between visits if side effects, questions, or changes come up.
| Chia access option | What it includes | Current starting price | Important note |
|---|---|---|---|
| PT-141 | Compounded PT-141 nasal spray, when prescribed | From $159/month | Online questionnaire, licensed provider review, 503A pharmacy dispensing, home delivery |
| Spark protocol | PT-141 nasal spray protocol | From $159/month | Prescription requires medical evaluation and is never guaranteed |
Who may not be a candidate for PT-141?
PT-141 may not be appropriate for people with certain blood pressure or cardiovascular risks. This is one reason prescription access should include clinician review, not just an online cart.
The Vyleesi label reports that bremelanotide can cause temporary blood pressure increases and heart-rate decreases after use. The label says Vyleesi is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease 1.
A clinician may also review nausea risk, migraine history, medication interactions, pregnancy or breastfeeding status where relevant, mental-health factors, and whether the sexual concern may have another cause. Professional guidance on HSDD stresses a broad biopsychosocial assessment rather than assuming one medication fits every patient 5.
Sometimes the safer next step is not PT-141. A clinician may recommend medication review, hormone evaluation, pelvic pain care, therapy, relationship support, a PDE5 inhibitor, or another plan depending on the main concern.
What side effects and safety issues should patients ask about?
The most common bremelanotide safety questions are nausea, flushing, headache, injection-site reactions for injectable products, and blood pressure or heart-rate changes. Ask about both common side effects and the risks that apply to your health history.
In Vyleesi clinical trials, nausea was the most commonly reported adverse reaction, and flushing, headache, vomiting, cough, fatigue, hot flush, paresthesia, dizziness, and nasal congestion were also reported in the FDA label 1. The RECONNECT trial publication also reported nausea, flushing, and headache among common treatment-emergent adverse events 2.
The blood pressure issue deserves special attention. FDA labeling describes transient increases in blood pressure and reductions in heart rate after bremelanotide, which is why cardiovascular history and blood pressure status are part of safety screening 1.
Long-term and off-label evidence also has limits. The strongest data are tied to specific trials, routes, and patient groups. Results are not established for compounded formulations, and individual results vary.
How does PT-141 compare with common alternatives?
PT-141 is not simply a “Viagra alternative.” It works through central melanocortin pathways, while sildenafil and tadalafil are PDE5 inhibitors that mainly affect blood-flow signaling.
| Option | Main mechanism | Common use | Evidence and safety notes |
|---|---|---|---|
| PT-141 / bremelanotide | Melanocortin receptor agonist acting in central nervous system pathways | FDA-approved as Vyleesi for acquired, generalized HSDD in certain premenopausal women | Can cause nausea, flushing, headache, blood pressure increase, and heart-rate decrease 1 |
| Sildenafil or tadalafil | PDE5 inhibition, supporting nitric-oxide-related blood-flow effects | Erectile dysfunction and other labeled uses depending on product | Different contraindications and interactions, including nitrate medication risks 6 |
| Vyleesi | FDA-approved bremelanotide injection | Acquired, generalized HSDD in certain premenopausal women | FDA-reviewed label, dosing, warnings, and adverse-event data 1 |
| Prescription compounded PT-141 | Compounded bremelanotide formulation prescribed for an individual patient | Use depends on clinician judgment and patient-specific review | Not FDA-approved; FDA does not evaluate compounded products before dispensing 7 |
| Research-use-only PT-141 | Laboratory peptide product, not a prescription drug for patient use | Research setting only | Not intended for human use; should not be treated as medication |
Nasal spray and injection forms should not be assumed to be interchangeable. The FDA-approved Vyleesi product is an injection, while Chia’s PT-141 offering is compounded nasal spray when prescribed. A clinician should explain the form being prescribed, why it was selected, and what is known or not known about that route.
What questions should you ask before starting PT-141?
Before starting PT-141, ask questions that separate your goal, safety profile, product source, and follow-up plan. Good care should make the “why” clear before any medication ships.
- 1Is my main concern desire, arousal, erection quality, orgasm, pain, relationship context, medication side effects, hormones, or another issue?
- 2Is my intended use FDA-approved or off-label?
- 3Do my blood pressure, heart history, migraines, medications, or other conditions affect my risk?
- 4What exact form is being prescribed, and which licensed pharmacy compounds or dispenses it?
- 5What side effects should I watch for, and how do I message the care team if they happen?
- 6What follow-up is included if the medication is not a fit?
If you want a licensed-provider review, you can start with Chia’s online eligibility quiz. The quiz is not a prescription by itself; it helps our providers review whether treatment may be clinically appropriate.
3-min quiz
Start a private online visit
Chia’s PT-141 access starts online and is reviewed by a licensed US provider. If prescribed, compounded PT-141 nasal spray is prepared by a state-licensed 503A pharmacy and shipped to your door. A prescription is not guaranteed, and compounded medications are not FDA-approved.
FAQ
You may see PT-141 sold online as a research peptide, but research-use-only products are not intended for human use. For patient use, the safer path is evaluation by a licensed clinician and dispensing through a licensed pharmacy when clinically appropriate.
PT-141 is another name for bremelanotide. Vyleesi is the FDA-approved bremelanotide injection for acquired, generalized HSDD in certain premenopausal women. A compounded PT-141 product is not the same as an FDA-approved product and is not FDA-approved.
Vyleesi is not FDA-approved for men. PT-141 has been studied and discussed for male sexual concerns, including erectile dysfunction, but that use is generally off-label or investigational and should be reviewed by a licensed clinician.
Not exactly. Viagra is sildenafil, a PDE5 inhibitor that mainly supports blood-flow signaling for erections. PT-141 works through melanocortin pathways in the brain. Which path makes sense depends on whether the main issue is desire, arousal, erection quality, or another cause.
Research-use-only PT-141 should not be used as human medication. These products are marketed for laboratory research, not prescribed patient care, and they may not come with clinician screening, pharmacy oversight, or follow-up.
Chia offers PT-141 nasal spray when prescribed after an online questionnaire and review by a licensed US provider. Prescribing is not guaranteed and depends on health history, goals, and safety factors.
Chia offers compounded PT-141 nasal spray. It is also available through Chia’s Spark protocol. If prescribed, medication is compounded by a state-licensed 503A pharmacy and shipped to the patient’s door.
People with cardiovascular disease, uncontrolled hypertension, or blood pressure concerns need clinician review before considering PT-141. Bremelanotide can cause temporary blood pressure increases and heart-rate decreases.
References
- 1.U.S. Food and Drug Administration. Vyleesi (bremelanotide injection) Prescribing Information. 2019.
- 2.Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology. 2019.
- 3.Nurnberg HG, Hensley PL, Heiman JR, Croft HA, Debattista C, Paine S. Bremelanotide for Treatment of Female Hypoactive Sexual Desire Disorder: A Review. Drug Design, Development and Therapy. 2022.
- 4.Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy male subjects and patients with mild-to-moderate erectile dysfunction. International Journal of Impotence Research. 2004.
- 5.Parish SJ, Goldstein AT, Goldstein SW, Goldstein I, Pfaus J, Clayton AH, Giraldi A, Simon JA, Davis SR, Kingsberg SA. Toward a More Evidence-Based Nosology and Nomenclature for Female Sexual Dysfunctions—Part II. Journal of Sexual Medicine. 2016.
- 6.American Urological Association. Erectile Dysfunction: AUA Guideline. 2018.
- 7.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. 2024.
- 8.ClinicalTrials.gov. Bremelanotide in Premenopausal Women With Female Sexual Dysfunction, NCT01382719. 2024.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if peptide therapy is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
